{"id":37283,"date":"2025-07-14T15:24:30","date_gmt":"2025-07-14T07:24:30","guid":{"rendered":"https:\/\/flcube.com\/?p=37283"},"modified":"2025-07-14T15:24:31","modified_gmt":"2025-07-14T07:24:31","slug":"dizals-sunvozertinib-included-in-nccn-guidelines-for-egfr-exon20ins-nsclc-treatment","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=37283","title":{"rendered":"Dizal’s Sunvozertinib Included in NCCN Guidelines for EGFR Exon20ins NSCLC Treatment"},"content":{"rendered":"\n

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192<\/a>) announced the inclusion of its sunvozertinib (trade name: Zegfrovy) in the U.S. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non\u2013Small Cell Lung Cancer (NSCLC). The drug is now recommended for previously treated EGFR exon 20 insertion mutation (exon20ins)-positive NSCLC.<\/p>\n\n\n\n

Sunvozertinib’s Approval and Recognition<\/strong>
Sunvozertinib is an oral, irreversible, and highly selective EGFR tyrosine kinase inhibitor (TKI) targeting multiple EGFR mutation subtypes. Earlier this month, it was approved in the US, becoming the first and only China-discovered innovative drug for EGFR exon20ins NSCLC to receive U.S. approval. This milestone also marks it as the first globally to achieve this recognition.<\/p>\n\n\n\n

NCCN Guidelines Inclusion<\/strong>
With its inclusion in the NCCN Guidelines, sunvozertinib now stands as the only small-molecule targeted therapy for EGFR exon20ins NSCLC endorsed by an international authoritative lung cancer guideline. This endorsement underscores the drug’s significance in the treatment landscape for this specific patient population.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) announced the inclusion of its sunvozertinib (trade name:…<\/p>\n","protected":false},"author":1,"featured_media":37285,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[1],"tags":[191,981],"class_list":["post-37283","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized","tag-dizal-pharmaceutical","tag-sha-688192"],"yoast_head":"\nDizal's Sunvozertinib Included in NCCN Guidelines for EGFR Exon20ins NSCLC Treatment - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) announced the inclusion of its sunvozertinib (trade name: Zegfrovy) in the U.S. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non\u2013Small Cell Lung Cancer (NSCLC). The drug is now recommended for previously treated EGFR exon 20 insertion mutation (exon20ins)-positive NSCLC.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=37283\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dizal's Sunvozertinib Included in NCCN Guidelines for EGFR Exon20ins NSCLC Treatment\" \/>\n<meta property=\"og:description\" content=\"China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) announced the inclusion of its sunvozertinib (trade name: Zegfrovy) in the U.S. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non\u2013Small Cell Lung Cancer (NSCLC). The drug is now recommended for previously treated EGFR exon 20 insertion mutation (exon20ins)-positive NSCLC.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=37283\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-14T07:24:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-14T07:24:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0312-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37283#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37283\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Dizal’s Sunvozertinib Included in NCCN Guidelines for EGFR Exon20ins NSCLC Treatment\",\"datePublished\":\"2025-07-14T07:24:30+00:00\",\"dateModified\":\"2025-07-14T07:24:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37283\"},\"wordCount\":182,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37283#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0312-1.webp\",\"keywords\":[\"Dizal Pharmaceutical\",\"SHA: 688192\"],\"articleSection\":[\"Others\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37283#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37283\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=37283\",\"name\":\"Dizal's Sunvozertinib Included in NCCN Guidelines for EGFR Exon20ins NSCLC Treatment - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37283#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37283#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0312-1.webp\",\"datePublished\":\"2025-07-14T07:24:30+00:00\",\"dateModified\":\"2025-07-14T07:24:31+00:00\",\"description\":\"China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) announced the inclusion of its sunvozertinib (trade name: Zegfrovy) in the U.S. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non\u2013Small Cell Lung Cancer (NSCLC). The drug is now recommended for previously treated EGFR exon 20 insertion mutation (exon20ins)-positive NSCLC.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37283#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37283\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37283#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0312-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0312-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Dizal's Sunvozertinib Included in NCCN Guidelines for EGFR Exon20ins NSCLC Treatment\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37283#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Dizal’s Sunvozertinib Included in NCCN Guidelines for EGFR Exon20ins NSCLC Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Dizal's Sunvozertinib Included in NCCN Guidelines for EGFR Exon20ins NSCLC Treatment - Insight, China's Pharmaceutical Industry","description":"China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) announced the inclusion of its sunvozertinib (trade name: Zegfrovy) in the U.S. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non\u2013Small Cell Lung Cancer (NSCLC). The drug is now recommended for previously treated EGFR exon 20 insertion mutation (exon20ins)-positive NSCLC.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=37283","og_locale":"en_US","og_type":"article","og_title":"Dizal's Sunvozertinib Included in NCCN Guidelines for EGFR Exon20ins NSCLC Treatment","og_description":"China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) announced the inclusion of its sunvozertinib (trade name: Zegfrovy) in the U.S. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non\u2013Small Cell Lung Cancer (NSCLC). The drug is now recommended for previously treated EGFR exon 20 insertion mutation (exon20ins)-positive NSCLC.","og_url":"https:\/\/flcube.com\/?p=37283","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-14T07:24:30+00:00","article_modified_time":"2025-07-14T07:24:31+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0312-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=37283#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=37283"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Dizal’s Sunvozertinib Included in NCCN Guidelines for EGFR Exon20ins NSCLC Treatment","datePublished":"2025-07-14T07:24:30+00:00","dateModified":"2025-07-14T07:24:31+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=37283"},"wordCount":182,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=37283#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0312-1.webp","keywords":["Dizal Pharmaceutical","SHA: 688192"],"articleSection":["Others"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=37283#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=37283","url":"https:\/\/flcube.com\/?p=37283","name":"Dizal's Sunvozertinib Included in NCCN Guidelines for EGFR Exon20ins NSCLC Treatment - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=37283#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=37283#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0312-1.webp","datePublished":"2025-07-14T07:24:30+00:00","dateModified":"2025-07-14T07:24:31+00:00","description":"China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) announced the inclusion of its sunvozertinib (trade name: Zegfrovy) in the U.S. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non\u2013Small Cell Lung Cancer (NSCLC). The drug is now recommended for previously treated EGFR exon 20 insertion mutation (exon20ins)-positive NSCLC.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=37283#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=37283"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=37283#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0312-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0312-1.webp","width":1080,"height":608,"caption":"Dizal's Sunvozertinib Included in NCCN Guidelines for EGFR Exon20ins NSCLC Treatment"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=37283#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Dizal’s Sunvozertinib Included in NCCN Guidelines for EGFR Exon20ins NSCLC Treatment"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0312-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37283","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=37283"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37283\/revisions"}],"predecessor-version":[{"id":37286,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37283\/revisions\/37286"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/37285"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=37283"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=37283"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=37283"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}